Rates of dissatisfaction high for hidradenitis suppurativa care

Rates of dissatisfaction high for hidradenitis suppurativa care

The rates of respondent dissatisfaction with current hidradenitis suppurativa (HS) treatment options are high, likely due to undertreatment with available therapies, according to a study published in the April issue of the Journal of Drugs in Dermatology.

SMC approves bimekizumab for hidradenitis suppurativa treatment

The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional systemic therapies. This approval makes Scotland the first country in the UK to offer bimekizumab for HS patients. HS is a chronic inflammatory skin condition affecting 0.77% of the UK population. […]